X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 9, 2012, Pages 1465-1474

  Kemp, Stephan ^a   Berger, Johannes ^b   Aubourg, Patrick ^c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Medical University of Vienna   (Austria)

^c BICÊTRE HOSPITAL   (France)

^d INSERM   (France)

Author keywords

ABCD1; ALDP; ELOVL1; Leukodystrophy; Peroxisome; VLCFA

Indexed keywords

ADRENOLEUKODYSTROPHY; BIOGENESIS; CHILDHOOD ADRENOLEUKODYSTROPHY; CLINICAL FEATURE; DEMYELINATING DISEASE; GENE MUTATION; GENETICS; HEREDITY; HETEROZYGOSITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PEROXISOME; PHENOTYPE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

ADRENOLEUKODYSTROPHY; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; FATTY ACIDS; FEMALE; HUMANS; MUTATION; PHENOTYPE; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84864042465     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.03.012     Document Type: Review

References (104)

1. Aubourg P. X-linked adrenoleukodystrophy. Handbook of Clinical Neurology 1996, vol. 66:447-483. Elsevier, Amsterdam. P.J. Vinken, C.W. Bruyn, H.W. Moser (Eds.).
2. Moser H.W., Mahmood A., Raymond G.V. X-linked adrenoleukodystrophy. Nat. Clin. Pract. Neurol. 2007, 3:140-151.
3. van Geel B.M., Bezman L., Loes D.J., Moser H.W., Raymond G.V. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann. Neurol. 2001, 49:186-194.
4. Chaudhry V., Moser H.W., Cornblath D.R. Nerve conduction studies in adrenomyeloneuropathy. J. Neurol. Neurosurg. Psychiatry 1996, 61:181-185.
5. O'Neill B.P., Moser H.W., Saxena K.M., Marmion L.C. Adrenoleukodystrophy: clinical and biochemical manifestations in carriers. Neurology 1984, 34:798-801.
6. Teriitehau C., Adamsbaum C., Merzoug V., Kalifa G., Tourbah A., Aubourg P. Subtle brain abnormalities in adrenomyeloneuropathy. J. Radiol. 2007, 88:957-961.
7. Ratai E., Kok T., Wiggins C., Wiggins G., Grant E., Gagoski B., O'Neill G., Adalsteinsson E., Eichler F. Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch. Neurol. 2008, 65:1488-1494.
8. Dubey P., Fatemi A., Huang H., Nagae-Poetscher L., Wakana S., Barker P.B., van Z.P., Moser H.W., Mori S., Raymond G.V. Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. Ann. Neurol. 2005, 58:758-766.
9. Fatemi A., Smith S.A., Dubey P., Zackowski K.M., Bastian A.J., van Zijl P.C., Moser H.W., Raymond G.V., Golay X. Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology 2005, 64:1739-1745.
10. Smith S.A., Golay X., Fatemi A., Mahmood A., Raymond G.V., Moser H.W., van Zijl P.C., Stanisz G.J. Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: application to adrenomyeloneuropathy. Magn. Reson. Med. 2009, 61:22-27.
11. Matsumoto H., Hanajima R., Terao Y., Hamada M., Yugeta A., Shirota Y., Yuasa K., Sato F., Matsukawa T., Takahashi Y., Goto J., Tsuji S., Ugawa Y. Efferent and afferent evoked potentials in patients with adrenomyeloneuropathy. Clin. Neurol. Neurosurg. 2010, 112:131-136.
12. Loes D.J., Hite S., Moser H., Stillman A.E., Shapiro E., Lockman L., Latchaw R.E., Krivit W. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am. J. Neuroradiol. 1994, 15:1761-1766.
13. Melhem E.R., Barker P.B., Raymond G.V., Moser H.W. X-linked adrenoleukodystrophy in children: review of genetic, clinical, and MR imaging characteristics. AJR Am. J. Roentgenol. 1999, 173:1575-1581.
14. Moser H.W., Smith K.D., Watkins P.A., Powers J., Moser A.B. X-linked adrenoleukodystrophy. The Metabolic and Molecular Bases of Inherited Disease 2001, 3257-3301. McGraw Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
15. Forsyth C.C., Forbes M., Cumings J.N. Adrenocortical atrophy and diffuse cerebral sclerosis. Arch. Dis. Child. 1971, 46:273-284.
16. Powers J.M., Schaumburg H.H. Adreno-leukodystrophy (sex-linked Schilder's disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am. J. Pathol. 1974, 76:481-491.
17. Johnson A.B., Schaumburg H.H., Powers J.M. Histochemical characteristics of the striated inclusions of adrenoleukodystrophy. J. Histochem. Cytochem. 1976, 24:725-730.
18. Igarashi M., Schaumburg H.H., Powers J., Kishmoto Y., Kolodny E., Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J. Neurochem. 1976, 26:851-860.
19. Singh I., Moser H.W., Moser A.B., Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem. Biophys. Res. Commun. 1981, 102:1223-1229.
20. Osmundsen H. Peroxisomal beta-oxidation of long fatty acids: effects of high fat diets. Ann. N. Y. Acad. Sci. 1982, 386:13-29.
21. Singh I., Moser A.E., Goldfischer S., Moser H.W. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:4203-4207.
22. Zhang X., De Marcos L.C., Schutte-Lensink N., Ofman R., Wanders R.J., Baldwin S.A., Baker A., Kemp S., Theodoulou F.L. Conservation of targeting but divergence in function and quality control of peroxisomal ABC transporters: an analysis using cross-kingdom expression. Biochem. J. 2011, 436:547-557.
23. Kemp S., Valianpour F., Mooyer P.A., Kulik W., Wanders R.J. Method for measurement of peroxisomal very-long-chain fatty acid {beta}-oxidation in human skin fibroblasts using stable-isotope-labeled tetracosanoic acid. Clin. Chem. 2004, 50:1824-1826.
24. Moser H.W., Moser A.B., Frayer K.K., Chen W., Schulman J.D., O'Neill B.P., Kishimoto Y. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981, 31:1241-1249.
25. Boehm C.D., Cutting G.R., Lachtermacher M.B., Moser H.W., Chong S.S. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol. Genet. Metab. 1999, 66:128-136.
26. Garashi M., Belchis D., Suzuki K. Brain gangliosides in adrenoleukodystrophy. J. Neurochem. 1976, 27:327-328.
27. Bizzozero O.A., Zuniga G., Lees M.B. Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. J. Neurochem. 1991, 56:872-878.
28. Theda C., Moser A.B., Powers J.M., Moser H.W. Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J. Neurol. Sci. 1992, 110:195-204.
29. Wilson R., Sargent J.R. Lipid and fatty acid composition of brain tissue from adrenoleukodystrophy patients. J. Neurochem. 1993, 61:290-297.
30. Bizzozero O.A., Good L.K., Evans J.E. Cysteine-108 is an acylation site in myelin proteolipid protein. Biochem. Biophys. Res. Commun. 1990, 170:375-382.
31. Hubbard W.C., Moser A.B., Tortorelli S., Liu A., Jones D., Moser H. Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings. Mol. Genet. Metab. 2006, 89:185-187.
32. Hubbard W.C., Moser A.B., Liu A.C., Jones R.O., Steinberg S.J., Lorey F., Panny S.R., Vogt R.F., Macaya D., Turgeon C.T., Tortorelli S., Raymond G.V. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol. Genet. Metab. 2009, 97:212-220.
33. Reinecke C.J., Knoll D.P., Pretorius P.J., Steyn H.S., Simpson R.H. The correlation between biochemical and histopathological findings in adrenoleukodystrophy. J. Neurol. Sci. 1985, 70:21-38.
34. Asheuer M., Bieche I., Laurendeau I., Moser A., Hainque B., Vidaud M., Aubourg P. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum. Mol. Genet. 2005, 14:1293-1303.
35. Ho J.K., Moser H., Kishimoto Y., Hamilton J.A. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J. Clin. Invest. 1995, 96:1455-1463.
36. Knazek R.A., Rizzo W.B., Schulman J.D., Dave J.R. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J. Clin. Invest. 1983, 72:245-248.
37. Whitcomb R.W., Linehan W.M., Knazek R.A. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J. Clin. Invest. 1988, 81:185-188.
38. Hein S., Schonfeld P., Kahlert S., Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum. Mol. Genet. 2008, 17:1750-1761.
39. Fourcade S., Lopez-Erauskin J., Galino J., Duval C., Naudi A., Jove M., Kemp S., Villarroya F., Ferrer I., Pamplona R., Portero-Otin M., Pujol A. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum. Mol. Genet. 2008, 17:1762-1773.
40. Pujol A., Hindelang C., Callizot N., Bartsch U., Schachner M., Mandel J.L. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet. 2002, 11:499-505.
41. Eichler F.S., Ren J.Q., Cossoy M., Rietsch A.M., Nagpal S., Moser A.B., Frosch M.P., Ransohoff R.M. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?. Ann. Neurol. 2008, 63:729-742.
42. Hashmi M., Stanley W., Singh I. Lignoceroyl-CoASH ligase: enzyme defect in fatty acid beta-oxidation system in X-linked childhood adrenoleukodystrophy. FEBS Lett. 1986, 196:247-250.
43. Mosser J., Douar A.M., Sarde C.O., Kioschis P., Feil R., Moser H., Poustka A.M., Mandel J.L., Aubourg P. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993, 361:726-730.
44. Jia Z., Moulson C.L., Pei Z., Miner J.H., Watkins P.A. Fatty acid transport protein 4 is the principal very long chain fatty acyl-CoA synthetase in skin fibroblasts. J. Biol. Chem. 2007, 282:20573-20583.
45. Shinnoh N., Yamada T., Yoshimura T., Furuya H., Yoshida Y., Suzuki Y., Shimozawa N., Orii T., Kobayashi T. Adrenoleukodystrophy: the restoration of peroxisomal beta-oxidation by transfection of normal cDNA. Biochem. Biophys. Res. Commun. 1995, 210:830-836.
46. Cartier N., Lopez J., Moullier P., Rocchiccioli F., Rolland M.O., Jorge P., Mosser J., Mandel J.L., Bougneres P.F., Danos O., Aubourg P. Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1674-1678.
47. Hettema E.H., van Roermund C.W., Distel B., van Den Berg M., Vilela C., Rodrigues-Pousada C., Wanders R.J., Tabak H.F. The ABC transporter proteins Pat1 and Pat2 are required for import of long-chain fatty acids into peroxisomes of Saccharomyces cerevisiae. EMBO J. 1996, 15:3813-3822.
48. Verleur N., Hettema E.H., van Roermund C.W., Tabak H.F., Wanders R.J. Transport of activated fatty acids by the peroxisomal ATP-binding-cassette transporter Pxa2 in a semi-intact yeast cell system. Eur. J. Biochem. 1997, 249:657-661.
49. van Roermund C.W.T., Visser W.F., IJlst L., van Cruchten A., Boek M., Kulik W., Waterham H.R., Wanders R.J.A. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J. 2008, 22:4201-4208.
50. Ofman R., Dijkstra I.M., van Roermund C.W., Burger N., Turkenburg M., van Cruchten A., van Engen C.E., Wanders R.J., Kemp S. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol. Med. 2010, 2:90-97.
51. Kemp S., Wanders R. Biochemical aspects of X-linked adrenoleukodystrophy. Brain Pathol. 2010, 20:831-837.
52. Kishimoto Y., Moser H.W., Kawamura N., Platt M., Pallante S.L., Fenselau C. Adrenoleukodystrophy: evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem. Biophys. Res. Commun. 1980, 96:69-76.
53. Tsuji S., Sano T., Ariga T., Miyatake T. Increased synthesis of hexacosanoic acid (C26:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J. Biochem. 1981, 90:1233-1236. (Tokyo).
54. Rizzo W.B., Avigan J., Chemke J., Schulman J.D. Adrenoleukodystrophy: very long-chain fatty acid metabolism in fibroblasts. Neurology 1984, 34:163-169.
55. Brown F.R., Van Duyn M.A., Moser A.B., Schulman J.D., Rizzo W.B., Snyder R.D., Murphy J.V., Kamoshita S., Migeon C.J., Moser H.W. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns. Hopkins. Med. J. 1982, 151:164-172.
56. Kemp S., Valianpour F., Denis S., Ofman R., Sanders R.J., Mooyer P., Barth P.G., Wanders R.J.A. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol. Genet. Metab. 2005, 84:144-151.
57. Wakil S.J. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989, 28:4523-4530.
58. Osei P., Suneja S.K., Laguna J.C., Nagi M.N., Cook L., Prasad M.R., Cinti D.L. Topography of rat hepatic microsomal enzymatic components of the fatty acid chain elongation system. J. Biol. Chem. 1989, 264:6844-6849.
59. Cinti D.L., Cook L., Nagi M.N., Suneja S.K. The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog. Lipid Res. 1992, 31:1-51.
60. Jakobsson A., Westerberg R., Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Prog. Lipid Res. 2006, 45:237-249.
61. Kemp S., Theodoulou F.L., Wanders R.J. Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance. Br. J. Pharmacol. 2011, 164:1753-1766.
62. Wang Y., Busin R., Reeves C., Bezman L., Raymond G., Toomer C.J., Watkins P.A., Snowden A., Moser A., Naidu S., Bibat G., Hewson S., Tam K., Clarke J.T., Charnas L., Stetten G., Karczeski B., Cutting G., Steinberg S. X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. Mol. Genet. Metab. 2011, 104:160-166.
63. Eichler E.E., Budarf M.L., Rocchi M., Deaven L.L., Doggett N.A., Baldini A., Nelson D.L., Mohrenweiser H.W. Interchromosomal duplications of the adrenoleukodystrophy locus: a phenomenon of pericentromeric plasticity. Hum. Mol. Genet. 1997, 6:991-1002.
64. Kemp S., Pujol A., Waterham H.R., van Geel B.M., Boehm C.D., Raymond G.V., Cutting G.R., Wanders R.J., Moser H.W. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum. Mutat. 2001, 18:499-515.
65. Dvorakova L., Storkanova G., Unterrainer G., Hujova J., Kmoch S., Zeman J., Hrebicek M., Berger J. Eight novel ABCD1 gene mutations and three polymorphisms in patients with X-linked adrenoleukodystrophy: the first polymorphism causing an amino acid exchange. Hum. Mutat. 2001, 18:52-60.
66. Yatsenko A.N., Shroyer N.F., Lewis R.A., Lupski J.R. Late-onset Stargardt disease is associated with missense mutations that map outside known functional regions of ABCR (ABCA4). Hum. Genet. 2001, 108:346-355.
67. Smith K.D., Kemp S., Braiterman L.T., Lu J.F., Wei H.M., Geraghty M., Stetten G., Bergin J.S., Pevsner J., Watkins P.A. X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem. Res. 1999, 24:521-535.
68. Berger J., Molzer B., Fae I., Bernheimer H. X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem. Biophys. Res. Commun. 1994, 205:1638-1643.
69. Raymond G.V., Seidman R., Monteith T.S., Kolodny E., Sathe S., Mahmood A., Powers J.M. Head trauma can initiate the onset of adreno-leukodystrophy. J. Neurol. Sci. 2010, 290:70-74.
70. Smith K.D., Sack G., Beaty T.H., Bergin A., Naidu S., Moser A., Moser H.W. A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am. J. Hum. Genet. 1991, 49:165.
71. Maestri N.E., Beaty T.H. Predictions of a 2-locus model for disease heterogeneity: application to adrenoleukodystrophy. Am. J. Med. Genet. 1992, 44:576-582.
72. Netik A., Forss-Petter S., Holzinger A., Molzer B., Unterrainer G., Berger J. Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum. Mol. Genet. 1999, 8:907-913.
73. Maier E.M., Mayerhofer P.U., Asheuer M., Kohler W., Rothe M., Muntau A.C., Roscher A.A., Holzinger A., Aubourg P., Berger J. X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem. Biophys. Res. Commun. 2008, 377:176-180.
74. Matsukawa T., Asheuer M., Takahashi Y., Goto J., Suzuki Y., Shimozawa N., Takano H., Onodera O., Nishizawa M., Aubourg P., Tsuji S. Identification of novel SNPs of ABCD1, ABCD2, ABCD3 and ABCD4 genes in patients with X-linked adrenoleukodystrophy (ALD) based on comprehensive resequencing and association studies with ALD phenotypes. Neurogenetics 2011, 12:41-50.
75. Berger J., Bernheimer H., Fae I., Braun A., Roscher A., Molzer B., Fischer G. Association of X-linked adrenoleukodystrophy with HLA DRB1 alleles. Biochem. Biophys. Res. Commun. 1995, 216:447-451.
76. McGuinness M.C., Powers J.M., Bias W.B., Schmeckpeper B.J., Segal A.H., Gowda V.C., Wesselingh S.L., Berger J., Griffin D.E., Smith K.D. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J. Neuroimmunol. 1997, 75:174-182.
77. Linnebank M., Kemp S., Wanders R.J.A., Kleijer W.J., van der Sterre M.L.T., Gartner J., Fliessbach K., Semmler A., Sokolowski P., Kohler W., Schlegel U., Schmidt S., Klockgether T., Wullner U. Methionine metabolism and phenotypic variability in X-linked adrenoleukodystrophy. Neurology 2006, 66:442-443.
78. Semmler A., Bao X., Cao G., Kohler W., Weller M., Aubourg P., Linnebank M. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J. Neurol. 2009, 256:1277-1280.
79. Brose R.D., Avramopoulos D., Smith K.D. SOD2 as a potential modifier of X-linked adrenoleukodystrophy clinical phenotypes. J. Neurol. 2012, doi:10.1007/s00415-011-6371-6378.
80. Barbier M., Sabbagh A., Kasper E., Asheuer M., Ahouansou O., Pribill I., Forss-Petter S., Vidaud M., Berger J., Aubourg P. CD1 gene polymorphisms and phenotypic variability in X-linked adrenoleukodystrophy. PLoS One 2012, 7:e29872.
81. Bodmer W., Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet. 2008, 40:695-701.
82. Devaney S.A., Palomaki G.E., Scott J.A., Bianchi D.W. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011, 306:627-636.
83. Powers J.M., DeCiero D.P., Ito M., Moser A.B., Moser H.W. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J. Neuropathol. Exp. Neurol. 2000, 59:89-102.
84. Fouquet F., Zhou J.M., Ralston E., Murray K., Troalen F., Magal E., Robain O., Dubois-Dalcq M., Aubourg P. Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Neurobiol. Dis. 1997, 3:271-285.
85. Hoftberger R., Kunze M., Weinhofer I., boul-Enein F., Voigtlander T., Oezen I., Amann G., Bernheimer H., Budka H., Berger J. Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol. Dis. 2007, 28:165-174.
86. Griffiths I., Klugmann M., Anderson T., Yool D., Thomson C., Schwab M.H., Schneider A., Zimmermann F., McCulloch M., Nadon N., Nave K.A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998, 280:1610-1613.
87. Lappe-Siefke C., Goebbels S., Gravel M., Nicksch E., Lee J., Braun P.E., Griffiths I.R., Nave K.A. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 2003, 33:366-374.
88. Lopez-Erauskin J., Fourcade S., Galino J., Ruiz M., Schluter A., Naudi A., Jove M., Portero-Otin M., Pamplona R., Ferrer I., Pujol A. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann. Neurol. 2011, 70:84-92.
89. Schluter A., Espinosa L., Fourcade S., Galino J., Lopez E., Ilieva E., Morato L., Asheuer M., Cook T., McLaren A., Reid J., Kelly F., Bates S., Aubourg P., Galea E., Pujol A. Functional genomic analysis unravels a metabolic-inflammatory interplay in adrenoleukodystrophy. Hum. Mol. Genet. 2012, 21:1062-1077.
90. Di Rocco M., Doria-Lamba L., Caruso U. Monozygotic twins with X-linked adrenoleukodystrophy and different phenotypes. Ann. Neurol. 2001, 50:424.
91. Korenke G.C., Fuchs S., Krasemann E., Doerr H.G., Wilichowski E., Hunneman D.H., Hanefeld F. Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann. Neurol. 1996, 40:254-257.
92. Jang J., Kang H.C., Kim H.S., Kim J.Y., Huh Y.J., Kim D.S., Yoo J.E., Lee J.A., Lim B., Lee J., Yoon T.M., Park I.H., Hwang D.Y., Daley G.Q., Kim D.W. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann. Neurol. 2011, 70:402-409.
93. Kassmann C.M., Nave K.A. Oligodendroglial impact on axonal function and survival - a hypothesis. Curr. Opin. Neurol. 2008, 21:235-241.
94. Kassmann C.M., Lappe-Siefke C., Baes M., Brugger B., Mildner A., Werner H.B., Natt O., Michaelis T., Prinz M., Frahm J., Nave K.A. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 2007, 39:969-976.
95. Khan M., Singh J., Singh I. Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J. Neurochem. 2008, 106:1766-1779.
96. Munn N.J., Arnio E., Liu D., Zoeller R.A., Liscum L. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J. Lipid Res. 2003, 44:182-192.
97. Maeba R., Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J. Lipid Res. 2003, 44:164-171.
98. Vejux A., Lizard G. Cytotoxic effects of oxysterols associated with human diseases: induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol. Aspects Med. 2009, 30:153-170.
99. Brites P., Waterham H.R., Wanders R.J. Functions and biosynthesis of plasmalogens in health and disease. Biochim. Biophys. Acta 2004, 1636:219-231.
100. Powers J.M., Liu Y., Moser A.B., Moser H.W. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J. Neuropathol. Exp. Neurol. 1992, 51:630-643.
101. Miller W.P., Rothman S.M., Nascene D., Kivisto T., DeFor T.E., Ziegler R.S., Eisengart J., Leiser K., Raymond G., Lund T.C., Tolar J., Orchard P.J. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 2011, 118:1971-1978.
102. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrere F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougneres P., Von K.C., Fischer A., Cavazzana-Calvo M., Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
103. Berger J., Pujol A., Aubourg P., Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol. 2010, 20:845-856.
104. Galino J., Ruiz M., Fourcade S., Schluter A., Lopez-Erauskin J., Guilera C., Jove M., Naudi A., Garcia-Arumi E., Andreu A.L., Starkov A.A., Pamplona R., Ferrer I., Portero-Otin M., Pujol A. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid. Redox. Signal. 2011, 15:2095-2107.